Terms: = Liver cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Treatment
462 results:
1. Clinical Phenotype and Disease Course of Inflammatory Bowel Disease in Iran: Results of the Iranian Registry of Crohn's and Colitis (IRCC).
Saberzadeh-Ardestani B; Khosravi AA; Mansour-Ghanaei F; Vahedi H; Baniasadi N; Seyyedmajidi M; Parhizkar B; Hormati A; Naghshbandi SJ; Matin S; Hassan Zadeh AA; Taghvaei T; Bahrami M; Rafeey M; Ahadi M; Vossoughinia H; Muosavi H; Gheibi S; Hosseini-Hemmatabadi RS; Yazdanbod A; Matinkhah S; Sheikh Esmaeili F; Fakheri H; Moosavy SH; Maleki I; Nasseri-Moghaddam S; Khosravi B; Farahmand F; Najafi M; Alimadadi H; Malekzadeh M; Anushiravani A; Kasaeian A; Alatab S; Sadeghi A; Radmard AR; Kolahdoozan S; Rajabi Z; Sima AR
Arch Iran Med; 2024 Apr; 27(4):183-190. PubMed ID: 38685844
[TBL] [Abstract] [Full Text] [Related]
2. Single-cell data revealed exhaustion of characteristic NK cell subpopulations and T cell subpopulations in hepatocellular carcinoma.
Cui Z; Li H; Liu C; Wang J; Chen C; Hu S; Zhao X; Li G
Aging (Albany NY); 2024 Apr; 16(7):6550-6565. PubMed ID: 38604154
[TBL] [Abstract] [Full Text] [Related]
3. Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitis.
Gudd CLC; Mitchell E; Atkinson SR; Mawhin MA; Turajlic S; Larkin J; Thursz MR; Goldin RD; Powell N; Antoniades CG; Woollard KJ; Possamai LA; Triantafyllou E
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580334
[TBL] [Abstract] [Full Text] [Related]
4. Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma.
Ohama H; Hiraoka A; Tada T; Hirooka M; Kariyama K; Hatanaka T; Tani J; Takaguchi K; Atsukawa M; Itobayashi E; Nishimura T; Tsuji K; Tajiri K; Ishikawa T; Yasuda S; Toyoda H; Fukunishi S; Ogawa C; Kakizaki S; Shimada N; Naganuma A; Kawata K; Kosaka H; Kuroda H; Matono T; Yata Y; Ochi H; Tada F; Nouso K; Morishita A; Itokawa N; Okubo T; Arai T; Tsutsui A; Nagano T; Yokohama K; Nishikawa H; Imai M; Koizumi Y; Nakamura S; Iijima H; Kaibori M; Hiasa Y; Kumada T;
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2042. PubMed ID: 38577725
[TBL] [Abstract] [Full Text] [Related]
5. Establishment of a murine hepatocellular carcinoma model by hydrodynamic injection and characterization of the immune tumor microenvironment.
Repáraz D; Casares N; Fuentes A; Navarro F
Methods Cell Biol; 2024; 185():79-97. PubMed ID: 38556453
[TBL] [Abstract] [Full Text] [Related]
6. First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.
Narayan R; Piérola AA; Donnellan WB; Yordi AM; Abdul-Hay M; Platzbecker U; Subklewe M; Kadia TM; Alonso-Domínguez JM; McCloskey J; Bradford K; Curtis M; Daskalakis N; Guttke C; Safer K; Hiebert B; Murphy J; Li X; Duchin K; Esteban D
Clin Transl Sci; 2024 Mar; 17(3):e13742. PubMed ID: 38494922
[TBL] [Abstract] [Full Text] [Related]
7. Primary hepatic Castleman disease.
Danis HE; Keenan C; Schaber J; Grasso SL
BMJ Case Rep; 2024 Mar; 17(3):. PubMed ID: 38479827
[TBL] [Abstract] [Full Text] [Related]
8. Immune checkpoint inhibitors associated cardiovascular immune-related adverse events.
Jo W; Won T; Daoud A; Čiháková D
Front Immunol; 2024; 15():1340373. PubMed ID: 38375475
[TBL] [Abstract] [Full Text] [Related]
9. Mucosal Genes Encoding Clock, Inflammation and Their Mutual Regulators Are Disrupted in Pediatric Patients with Active Ulcerative Colitis.
Labes S; Froy O; Tabach Y; Shamir R; Shouval DS; Weintraub Y
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338765
[TBL] [Abstract] [Full Text] [Related]
10. The safety and efficacy of systemic delivery of a new liver-de-targeted TGFβ signaling inhibiting adenovirus in an immunocompetent triple negative mouse mammary tumor model.
Shin SC; Vickman RE; Filimon B; Yang Y; Hu Z; Mangold KA; Prabhakar BS; Schreiber H; Xu W
Cancer Gene Ther; 2024 Apr; 31(4):574-585. PubMed ID: 38267626
[TBL] [Abstract] [Full Text] [Related]
11. Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid Metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data.
Qu Y; Gong X; Zhao Z; Zhang Z; Zhang Q; Huang Y; Xie Q; Liu Y; Wei J; Du H
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255993
[TBL] [Abstract] [Full Text] [Related]
12. Macro CD5L
Lu JC; Wu LL; Sun YN; Huang XY; Gao C; Guo XJ; Zeng HY; Qu XD; Chen Y; Wu D; Pei YZ; Meng XL; Zheng YM; Liang C; Zhang PF; Cai JB; Ding ZB; Yang GH; Ren N; Huang C; Wang XY; Gao Q; Sun QM; Shi YH; Qiu SJ; Ke AW; Shi GM; Zhou J; Sun YD; Fan J
Nat Commun; 2024 Jan; 15(1):621. PubMed ID: 38245530
[TBL] [Abstract] [Full Text] [Related]
13. Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma.
France NL; Blair HA
Target Oncol; 2024 Jan; 19(1):115-123. PubMed ID: 38236364
[TBL] [Abstract] [Full Text] [Related]
14. Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma.
Monge C; Xie C; Myojin Y; Coffman-D'Annibale KL; Hrones D; Brar G; Wang S; Budhu A; Figg WD; Cam M; Finney R; Levy EB; Kleiner DE; Steinberg SM; Wang XW; Redd B; Wood BJ; Greten TF
Cancer Med; 2024 Feb; 13(3):e6912. PubMed ID: 38205877
[TBL] [Abstract] [Full Text] [Related]
15. Immune checkpoint inhibitor-associated colitis in unresectable hepatocellular carcinoma: two cases of early onset after treatment with durvalumab plus tremelimumab.
Abe H; Endo K; Kuroda H; Oikawa T; Abe T; Ito A; Suzuki A; Yoshida Y; Kakisaka K; Matsumoto T
Clin J Gastroenterol; 2024 Apr; 17(2):307-310. PubMed ID: 38185741
[TBL] [Abstract] [Full Text] [Related]
16. Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients.
Ko B; Tao K; Brennan L; Rakhade S; Chan CX; Moone JY; Zhu R; Sher A; Wang S; Bracero Y; Fullerton B; McLellan B; Geskin LJ; Saenger YM
Melanoma Res; 2024 Apr; 34(2):134-141. PubMed ID: 38181115
[TBL] [Abstract] [Full Text] [Related]
17. Bioinformatic Analysis and Computer-Aided Study to Investigate the Potential Application of a Bioflavonoid Compound Bilobetin in liver cancer treatment.
Zhang C; Sui Y; Liu S; Yang M
Front Biosci (Landmark Ed); 2023 Dec; 28(12):360. PubMed ID: 38179744
[TBL] [Abstract] [Full Text] [Related]
18. Lymphocyte subsets and inflammatory factors as predictors of immunotherapy efficacy in patients with hepatocellular carcinoma.
Shuyue G; Jiamin C; Niansong Q
Sci Rep; 2023 Dec; 13(1):22480. PubMed ID: 38110467
[TBL] [Abstract] [Full Text] [Related]
19. Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015-2018 in Greece. The 'SUMMER' study: a retrospective multicenter chart review project.
Bafaloukos D; Kouzis P; Gouveris P; Boukovinas I; Kalbakis K; Baka S; Kyriakakis G; Moschou D; Molfeta A; Demiri S; Mavroudis D; Spanoudi F; Dimitriadis I; Gogas H
Melanoma Res; 2024 Apr; 34(2):152-165. PubMed ID: 38092014
[TBL] [Abstract] [Full Text] [Related]
20. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal cancer after treatment Termination.
Simmons K; Thomas JV; Ludford K; Willis JA; Higbie VS; Raghav KPS; Johnson B; Dasari A; Kee BK; Parseghian CM; Lee MS; Le PH; Morelli MP; Shen JP; Bent A; Vilar E; Wolff RA; Kopetz S; Overman MJ; Morris VK
Cancer Res Commun; 2023 Dec; 3(12):2510-2517. PubMed ID: 38085001
[TBL] [Abstract] [Full Text] [Related]
[Next]
